Li Y, et al. - In this post hoc analysis of an interventional trial, researchers assessed the modifying influence of vitamin B₁₂ (B₁₂) levels on the link between folic acid treatment and chronic kidney disease (CKD) progression among hypertensive adults with mild to moderate CKD. Participants (n = 1,374) were selected from the kidney disease substudy of the China Stroke Primary Prevention Trial, which was performed in 20 communities in Jiangsu province in China, an area with low folate intake. B₁₂ measurements were taken at baseline. The participants were allocated to a double-blinded daily treatment of enalapril, 10 mg, and folic acid, 0.8 mg; or enalapril, 10 mg, alone. Mean baseline estimated glomerular filtration rate was 86.1 ± 20.5 (SD) mL/min/1.73 m² and median treatment duration was 4.4 years. A greater reduction in the odds of CKD progression was observed in relation to folic acid treatment in patients with mild to moderate CKD and higher B₁₂ levels.